Marché mondial des médicaments contre l’hypercholestérolémie – Tendances et prévisions du secteur jusqu’en 2030

Analyse et taille du marché des médicaments contre l'hypercholestérolémie

Le marché des médicaments contre l'hypercholestérolémie devrait connaître une croissance majeure au cours de la période de prévision. L'augmentation des cas d'hypertension, de cardiomyopathie et de diabète stimule la croissance du marché. Des facteurs tels que l'adaptation à des modes de vie malsains, l'augmentation du stress dans la vie quotidienne et la malnutrition, ainsi que les antécédents familiaux de maladie cardiaque, augmentent également la croissance du marché. Plusieurs acteurs majeurs du marché contribuent grandement à la découverte et au développement de médicaments. Le COVID-19 a également eu un impact majeur sur la croissance du marché.

Data Bridge Market Research analyse le taux de croissance du marché des médicaments contre l'hypercholestérolémie au cours de la période de prévision 2023-2030. Le TCAC attendu du marché des médicaments contre l'hypercholestérolémie a tendance à être d'environ 16,00 % au cours de la période de prévision mentionnée. Le marché était évalué à 13 milliards USD en 2022 et atteindrait 42,62 milliards USD d'ici 2030. En plus des informations sur le marché telles que la valeur marchande, le taux de croissance, les segments de marché, la couverture géographique, les acteurs du marché et le scénario du marché, le rapport de marché organisé par l'équipe de Data Bridge Market Research comprend également une analyse approfondie des experts, l'épidémiologie des patients, l'analyse du pipeline, l'analyse des prix et le cadre réglementaire.

Portée et segmentation du marché des médicaments contre l'hypercholestérolémie

Market Definition

Hypercholesterolemia is a condition in which an excessive amount of cholesterol is present in the blood. It is increased by unhealthy eating, underrated thyroid level, and other chronic diseases such as heart diseases, diabetes, and others. Hypercholesterolemia is a serious life-threatening condition wherein hypercholesterolemia drugs are used to decrease the level of bad cholesterol in the blood. The primary cause may be genetic, and the secondary maybe environmental factors.

Global Hypercholesterolemia Drugs Market Dynamics

Drivers

• Increase in Hypercholesterolemia

According to the World Health Organization (WHO), hypercholesterolemia is projected to result in more than 2.6 million deaths yearly. Almost 37.0% of adults in the U.S. have high LDL-C levels. Yet, less than 50.0% of patients who receive any treatment and around 33.0% of patients undergoing treatment cannot achieve normal lipid levels. Thus, it boosts the demand in the hypercholesterolemia drugs market.

• Increased Clinical Studies and Government Initiatives

The market is estimated to be driven by the rising R&D investments in drug discovery and development and the growing prevalence of diabetes. For instance, according to the reports of the International Diabetes Federation, for treating diabetes as a metabolic syndrome, around 415 million people are currently affected by diabetes worldwide, and it is hoped to increase to 642 million diabetic people by the year 2040. Thus, these increasing clinical activities are boosting the growth of the market.

Opportunities

• Increasing Demand for Statins

Statins are recommended, and the market is driven by several advantages, such as enhanced endothelial function, decreased oxidative stress-induced cell damage, increased atherosclerotic plaque stability, and reduced inflammation. In addition, PCSK9 inhibitors are estimated to increase in popularity during the forecast period because of the sharp decline in blood LDL levels.

• Rising Demand for Drug Therapy

Drug therapy is driving the market because of its widespread usage, ease of administration, and high-reliability rate. This therapy is estimated to maintain its growth even due to its advanced ways of administering medicines without disturbing daily patient lives. Furthermore, the launch of smart drug delivery devices and smart dosage control methods is projected to boost the segment further.

Restraints/Challenges

• Lack of Skilled Professionals

A lack of trained healthcare professionals who are unaware of the appropriate treatment methods for this disease could reduce the growth of the global hypercholesterolemia drugs market during a forecast period.

• Adverse Side-Effects Associated with Hypercholesterolemia Drugs

Most hypercholesterolemia drugs are associated with adverse effects such as liver damage or type 2 diabetes. Drug classes such as CETP inhibitors have been withdrawn or discontinued even in the later stages of trials because of the adverse effects or failure to achieve satisfactory results. Risks associated with antihyperlipidemic pose a significant challenge to their entry into the market.

This global hypercholesterolemia drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global hypercholesterolemia drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Hypercholesterolemia Drugs Market Scope

The global hypercholesterolemia drugs market is segmented on the basis of drug class, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Class

• Statins
• Bile-Acid-Binding Resins
• Cholesterol Absorption Inhibitors
• PCSK9 Inhibitors
• Combination
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Homecare
• Speciality Centres
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Hypercholesterolemia Drugs Market Regional Analysis/Insights

The global hypercholesterolemia drugs market is analysed and market size insights and trends are provided by drug class, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global hypercholesterolemia drugs market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is expected to have the highest market due to the region's increased R&D activities on liver diseases and well-established healthcare infrastructure.

Asia Pacific dominates the market due to increased advancement in technology and growth and expansion of healthcare infrastructure in the region.  

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Hypercholesterolemia Drugs Market Share Analysis

The global hypercholesterolemia drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global hypercholesterolemia drugs market.

Key players operating in the global hypercholesterolemia drugs market include:

• Pfizer Inc. (U.S.)
• Novartis AG (Switzerland)
• Amgen Inc. (U.S.)
• Boehringer Ingelheim International GmbH. (Germany)
• Merck & Co Inc. (U.S.)
• Sun Pharmaceutical Industries Ltd. (India)
• Teva Pharmaceuticals Industries Ltd. (Israel)
• AstraZeneca (U.K.)
• Fresenius Kabi AG (Germany)
• Bayer AG (Germany)
• Aurobindo Pharma (India)
• AbbVie Inc. (Ireland)
• Melinta Therapeutics, Inc (U.S.)

Research Methodology: Global Hypercholesterolemia Drugs Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry.

La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données, qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). En dehors de cela, les modèles de données comprennent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement de l'entreprise, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et la part des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande de renseignements pour parler à nos experts du secteur.

Personnalisation disponible

Data Bridge Market Research est un leader dans la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'aux stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez pour obtenir des données dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Factbook) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.

SKU-55652